Nickolai A Barlev

List of Publications by Citations

67 papers	5,216 citations	24 h-index	72 g-index
74 ext. papers	6,657 ext. citations	6.3 avg, IF	4.89 L-index

#	Paper	IF	Citations
67	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. *Cell Death and Differentiation*, **2018**, 25, 486-541	12.7	2160
66	Regulation of p53 activity through lysine methylation. *Nature*, **2004**, 432, 353-60	50.4	620
65	Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. *Molecular Cell*, **2001**, 8, 1243-54	17.6	587
64	Activating signal cointegrator 2 belongs to a novel steady-state complex that contains a subset of trithorax group proteins. *Molecular and Cellular Biology*, **2003**, 23, 140-9	4.8	190
63	Characterization of physical interactions of the putative transcriptional adaptor, ADA2, with acidic activation domains and TATA-binding protein. *Journal of Biological Chemistry*, **1995**, 270, 19337-44	5.4	155
62	Crystal structure of yeast Esa1 suggests a unified mechanism for catalysis and substrate binding by histone acetyltransferases. *Molecular Cell*, **2000**, 6, 1195-205	17.6	141
61	Methylation-acetylation interplay activates p53 in response to DNA damage. *Molecular and Cellular Biology*, **2007**, 27, 6756-69	4.8	138
60	Repression of GCN5 histone acetyltransferase activity via bromodomain-mediated binding and phosphorylation by the Ku-DNA-dependent protein kinase complex. *Molecular and Cellular Biology*, **1998**, 18, 1349-58	4.8	108
59	Specific Drug Delivery to Cancer Cells with Double-Imprinted Nanoparticles against Epidermal Growth Factor Receptor. *Nano Letters*, **2018**, 18, 4641-4646	11.5	84
58	EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2019**, 1871, 29-39	11.2	71
57	Lysine-specific modifications of p53: a matter of life and death?. *Oncotarget*, **2013**, 4, 1556-71	3.3	67
56	One-carbon metabolism and nucleotide biosynthesis as attractive targets for anticancer therapy. *Oncotarget*, **2017**, 8, 23955-23977	3.3	67
55	The 26S proteasome is a multifaceted target for anti-cancer therapies. *Oncotarget*, **2015**, 6, 24733-49	3.3	61
54	The biological basis and clinical symptoms of CAR-T therapy-associated toxicites. *Cell Death and Disease*, **2018**, 9, 897	9.8	59
53	A novel human Ada2 homologue functions with Gcn5 or Brg1 to coactivate transcription. *Molecular and Cellular Biology*, **2003**, 23, 6944-57	4.8	51
52	Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis. *Cell Death and Disease*, **2019**, 10, 902	9.8	46
51	Proteomic analysis of the 20S proteasome (PSMA3)-interacting proteins reveals a functional link between the proteasome and mRNA metabolism. *Biochemical and Biophysical Research Communications*, **2011**, 416, 258-65	3.4	39

50	DNA damage-induced ubiquitylation of proteasome controls its proteolytic activity. *Oncotarget*, **2013**, 4, 1338-48	3.3	39
49	BTK Modulates p53 Activity to Enhance Apoptotic and Senescent Responses. *Cancer Research*, **2016**, 76, 5405-14	10.1	37
48	26S proteasome exhibits endoribonuclease activity controlled by extra-cellular stimuli. *Cell Cycle*, **2010**, 9, 840-9	4.7	33
47	Role of proteasomes in transcription and their regulation by covalent modifications. *Frontiers in Bioscience - Landmark*, **2008**, 13, 7184-92	2.8	30
46	KMT Set7/9 affects genotoxic stress response via the Mdm2 axis. *Oncotarget*, **2015**, 6, 25843-55	3.3	29
45	DNA damage modulates interactions between microRNAs and the 26S proteasome. *Oncotarget*, **2014**, 5, 3555-67	3.3	24
44	Isatin-Schiff base-copper (II) complex induces cell death in p53-positive tumors. *Cell Death Discovery*, **2018**, 4, 103	6.9	24
43	BTK: a two-faced effector in cancer and tumour suppression. *Cell Death and Disease*, **2018**, 9, 1064	9.8	21
42	Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2. *Cell Death and Disease*, **2018**, 9, 257	9.8	20
41	TG2 regulates the heat-shock response by the post-translational modification of HSF1. *EMBO Reports*, **2018**, 19,	6.5	20
40	Role of ACTN4 in Tumorigenesis, Metastasis, and EMT. *Cells*, **2019**, 8,	7.9	19
39	Extracellular Proteasomes Are Deficient in 19S Subunits as Revealed by iTRAQ Quantitative Proteomics. *Journal of Cellular Physiology*, **2017**, 232, 842-851	7	19
38	Current genome editing tools in gene therapy: new approaches to treat cancer. *Current Gene Therapy*, **2015**, 15, 511-29	4.3	19
37	BTK blocks the inhibitory effects of MDM2 on p53 activity. *Oncotarget*, **2017**, 8, 106639-106647	3.3	18
36	Orphan receptor NR4A3 is a novel target of p53 that contributes to apoptosis. *Oncogene*, **2019**, 38, 2108-2122	9.2	18
35	E3 ubiquitin ligase Pirh2 enhances tumorigenic properties of human non-small cell lung carcinoma cells. *Genes and Cancer*, **2016**, 7, 383-393	2.9	17
34	Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 5197-5202	2.9	16
33	Autophagy suppresses the pathogenic immune response to dietary antigens in cystic fibrosis. *Cell Death and Disease*, **2019**, 10, 258	9.8	13

32	TAp73 transcriptionally represses BNIP3 expression. *Cell Cycle*, **2015**, 14, 2484-93	4.7	13
31	Novel isatin-derived molecules activate p53 via interference with Mdm2 to promote apoptosis. *Cell Cycle*, **2018**, 17, 1917-1930	4.7	13
30	Co-expression of RelA/p65 and ACTN4 induces apoptosis in non-small lung carcinoma cells. *Cell Cycle*, **2018**, 17, 616-626	4.7	11
29	Proteomic analysis of ACTN4-interacting proteins reveals it□s a putative involvement in mRNA metabolism. *Biochemical and Biophysical Research Communications*, **2010**, 397, 192-6	3.4	11
28	Simultaneous EGFP and tag labeling of the □ subunit for live imaging and affinity purification of functional human proteasomes. *Molecular Biotechnology*, **2015**, 57, 36-44	3	10
27	Lysine-specific post-translational modifications of proteins in the life cycle of viruses. *Cell Cycle*, **2019**, 18, 1995-2005	4.7	9
26	Nutlin sensitizes lung carcinoma cells to interferon-alpha treatment in MDM2-dependent but p53-independent manner. *Biochemical and Biophysical Research Communications*, **2018**, 495, 1233-1239	3.4	9
25	Interplay between p53 and non-coding RNAs in the regulation of EMT in breast cancer. *Cell Death and Disease*, **2021**, 12, 17	9.8	8
24	The p53 family member p73 in the regulation of cell stress response. *Biology Direct*, **2021**, 16, 23	7.2	7
23	Ca -depended signaling pathways regulate self-renewal and pluripotency of stem cells. *Cell Biology International*, **2018**, 42, 1086-1096	4.5	7
22	Combined treatment of human multiple myeloma cells with bortezomib and doxorubicin alters the interactome of 20S proteasomes. *Cell Cycle*, **2018**, 17, 1745-1756	4.7	6
21	Effects of Mycoplasmas on the Host Cell Signaling Pathways. *Pathogens*, **2020**, 9,	4.5	5
20	Attenuation of p53 mutant as an approach for treatment Her2-positive cancer. *Cell Death Discovery* , **2020**, 6, 100	6.9	5
19	Effects of mycoplasma infection on the host organism response via p53/NF-□ signaling. *Journal of Cellular Physiology*, **2018**, 234, 171-180	7	4
18	Activating Effect of 3-Benzylidene Oxindoles on AMPK: From Computer Simulation to High-Content Screening. *ChemMedChem*, **2020**, 15, 2521-2529	3.7	4
17	Set7/9 controls proliferation and genotoxic drug resistance of NSCLC cells. *Biochemical and Biophysical Research Communications*, **2021**, 572, 41-48	3.4	4
16	Regulation of Endoribonuclease Activity of Alpha-Type Proteasome Subunits in Proerythroleukemia K562 Upon Hemin-Induced Differentiation. *Protein Journal*, **2016**, 35, 17-23	3.9	3
15	Immunoaffinity purification of the functional 20S proteasome from human cells via transient overexpression of specific proteasome subunits. *Protein Expression and Purification*, **2014**, 97, 37-43	2	3

List of Publications

14	Nano-molecularly imprinted polymers (nanoMIPs) as a novel approach to targeted drug delivery in nanomedicine.. *RSC Advances*, **2022**, 12, 3957-3968	3.7	3
13	SEMG1/2 augment energy metabolism of tumor cells. *Cell Death and Disease*, **2020**, 11, 1047	9.8	3
12	KMT Set7/9 is a new regulator of Sam68 STAR-protein. *Biochemical and Biophysical Research Communications*, **2020**, 525, 1018-1024	3.4	2
11	Hot and toxic: hyperthermia and anti-mitotic drugs in cancer therapy. *Cell Cycle*, **2013**, 12, 2533	4.7	2
10	Zeb1-mediated autophagy enhances resistance of breast cancer cells to genotoxic drugs. *Biochemical and Biophysical Research Communications*, **2021**, 589, 29-34	3.4	2
9	Proteomic Analysis of Zeb1 Interactome in Breast Carcinoma Cells. *Molecules*, **2021**, 26,	4.8	2
8	The RNA-binding protein HuR is a novel target of Pirh2 E3 ubiquitin ligase. *Cell Death and Disease*, **2021**, 12, 581	9.8	2
7	p53-Independent Effects of Set7/9 Lysine Methyltransferase on Metabolism of Non-Small Cell Lung Cancer Cells. *Frontiers in Oncology*, **2021**, 11, 706668	5.3	1
6	Distinct p63 and p73 Protein Interactions Predict Specific Functions in mRNA Splicing and Polyploidy Control in Epithelia. *Cells*, **2020**, 10,	7.9	1
5	The Role of ERBB2/HER2 Tyrosine Kinase Receptor in the Regulation of Cell Death. *Biochemistry (Moscow)*, **2020**, 85, 1277-1287	2.9	1
4	Emerging roles of cancer-testis antigenes, semenogelin 1 and 2, in neoplastic cells. *Cell Death Discovery*, **2021**, 7, 97	6.9	1
3	Regulation of autophagy flux by E3 ubiquitin ligase Pirh2 in lung cancer. *Biochemical and Biophysical Research Communications*, **2021**, 563, 119-125	3.4	1
2	Sea Urchin as a Universal Model for Studies of Gene Networks. *Frontiers in Genetics*, **2020**, 11, 627259	4.5	1
1	Analysis of activity and regulation of hGcn5, a human histone acetyltransferase. *Methods in Enzymology*, **1999**, 304, 696-715	1.7	